Drug ID: 3d00000004
Drug Name: Cabozantinib
Generic Names: Cometriq
Legal Status: Non Opioid Prescription only drug
Indication for Mother: Category D
There is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience or studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.
Recommended Dose: The recommended dose is 140 mg orally, once daily.
Recommended In: This medication is an anti-neoplstic agent (kinase inhibitor), prescribed for medullary thyroid cancer. It stops the growth of cancer cells by by blocking Tyrosine kinases.
Directions For Use: It comes as a capsule to take by mouth, on an empty stomach.
Storage: Store it at room temperature (20°C to 25°C).
Dosage Forms: Capsule
Side Effects: Most Common - Diarrhea, mouth ulcer, palmar-plantar erythrodysesthesia syndrome (PPES), decreased weight, decreased appetite, nausea, fatigue, mouth pain, hair color changes, taste disorder, high blood pressure, abdominal pain, and constipation.
Serious Effects - Coughing up blood or blood clots, blood vomiting, black stools, unusual bleeding.
In Case of Overdose: If overdose is suspected, contact a poison control center or emergency room immediately.
Avoid If: Caution should be exercised in patients with history of high blood pressure, coughing up blood or bleeding, open wound, liver problems, any allergy, who are taking other medications, during pregnancy and breastfeeding.
Patient may develop severe bleeding episodes (serious effects) that can lead to death. If it is so consult with your healthcare provider.
Stop this medication immediately if you have experienced any one of the following: fistula formation, severe hemorrhage, heart attack, stroke, nephrotic syndrome, osteonecrosis of the jaw and leukoencephalopathy syndrome.
Drug Interaction: Other medications can affect the removal of cabozantinib from your body, which may affect how cabozantinib works. One example is St. John's wort, among others.